Kovitz Investment Group Partners LLC Acquires New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Kovitz Investment Group Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,431 shares of the biopharmaceutical company's stock, valued at approximately $669,000.

Several other institutional investors have also recently made changes to their positions in the company. Sphera Funds Management LTD. purchased a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $1,925,000. SYM FINANCIAL Corp raised its position in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock worth $260,000 after purchasing an additional 55 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Alnylam Pharmaceuticals by 50.3% in the 3rd quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company's stock valued at $926,000 after buying an additional 1,126 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $7,009,000. Finally, Ikarian Capital LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth about $2,404,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a "neutral" rating in a research report on Monday, August 26th. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Royal Bank of Canada reiterated an "outperform" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $298.09.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 1,682 shares of the firm's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares of the company's stock, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,370 shares of company stock valued at $2,100,703 in the last ninety days. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded up $0.04 during mid-day trading on Friday, hitting $245.30. The stock had a trading volume of 222,198 shares, compared to its average volume of 859,407. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The company's 50-day simple moving average is $267.46 and its 200-day simple moving average is $247.48. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. The business's revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.15 EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.